"Prevent Calamity" Jane

  • by: |
  • 12/20/2012

Subject: Leadership Changes in the Office of Regulatory Policy

CDER Staff:

I would like to make you aware of an upcoming important transition in CDER. Effective January 6, 2013, Jane Axelrad will be leaving her post as head of the Office of Regulatory Policy (ORP) to assume a new role, on detail, as senior advisor to me.

In this new role, Jane will serve as the Agency lead on managing policy, surveillance and enforcement, legislative, and oversight issues related to pharmacy compounding arising out of the meningitis outbreak. As time permits, she will also manage various other high-priority projects that cut across office lines. 

Denise Esposito will serve as acting director of ORP until at least February 1, 2013, following which she will be leaving ORP to assume a management position elsewhere in the Agency. While Denise is serving as acting director of ORP, Nancy Hayes will serve as acting deputy director. When Denise leaves for her new position, Nancy Hayes will serve as acting director until the position is filled permanently.

As you know, Jane has been the associate director for policy, CDER, for more than 20 years, and she has led ORP for more than 15 years. Jane’s expertise on various legislative and policy issues is well recognized, and she is much sought after on a variety of matters. 

Because her involvement in pharmacy compounding will take up most of her time, she has expressed the desire to step out of the management of ORP so that she will be able to devote the necessary time to compounding and other policy projects. With Denise’s impending departure, I want to establish a plan during this transition to ensure the continued stability of ORP, which performs so many vital functions for the Center.

Denise has been with CDER for two and a half years, and she has made important contributions on a number of different issues, as well as serving as Jane’s deputy during this time of intense activity in CDER. We are grateful that we will still have the benefit of her skills and expertise at FDA.

Janet Woodcock


Center for Medicine in the Public Interest is a nonprofit, non-partisan organization promoting innovative solutions that advance medical progress, reduce health disparities, extend life and make health care more affordable, preventive and patient-centered. CMPI also provides the public, policymakers and the media a reliable source of independent scientific analysis on issues ranging from personalized medicine, food and drug safety, health care reform and comparative effectiveness.

Blog Roll

Alliance for Patient Access Alternative Health Practice
Better Health
Biotech Blog
CA Medicine man
Cafe Pharma
Campaign for Modern Medicines
Carlat Psychiatry Blog
Clinical Psychology and Psychiatry: A Closer Look
Conservative's Forum
Club For Growth
Diabetes Mine
Disruptive Women
Doctors For Patient Care
Dr. Gov
Drug Channels
DTC Perspectives
Envisioning 2.0
FDA Law Blog
Fierce Pharma
Fresh Air Fund
Furious Seasons
Gel Health News
Hands Off My Health
Health Business Blog
Health Care BS
Health Care for All
Healthy Skepticism
Hooked: Ethics, Medicine, and Pharma
Hugh Hewitt
In the Pipeline
In Vivo
Internet Drug News
Jaz'd Healthcare
Jaz'd Pharmaceutical Industry
Jim Edwards' NRx
Kaus Files
Laffer Health Care Report
Little Green Footballs
Med Buzz
Media Research Center
More than Medicine
National Review
Neuroethics & Law
Nurses For Reform
Nurses For Reform Blog
Opinion Journal
Orange Book
Peter Rost
Pharm Aid
Pharma Blog Review
Pharma Blogsphere
Pharma Marketing Blog
Pharmacology Corner
Pharmaceutical Business Review
Piper Report
Prescription for a Cure
Public Plan Facts
Real Clear Politics
Shark Report
Shearlings Got Plowed
Taking Back America
Terra Sigillata
The Cycle
The Catalyst
The Lonely Conservative
Town Hall
Washington Monthly
World of DTC Marketing
WSJ Health Blog